相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio
Susan E. Bates et al.
CLINICAL CANCER RESEARCH (2015)
Romidepsin for the treatment of non-Hodgkin's lymphoma
Victor Y. Yazbeck et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Promising therapies for the treatment of chronic lymphocytic leukemia
Fortunato Morabito et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Treatment options for mantle cell lymphoma
Piotr Smolewski et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Emerging drugs for diffuse large B-cell lymphoma
Patrizia Mondello et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?
Jennifer K. Lue et al.
CURRENT ONCOLOGY REPORTS (2015)
BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma
Cristina Correia et al.
BLOOD (2015)
Cutaneous T-cell lymphoma: 2014 Update on diagnosis, risk-stratification, and management
Ryan A. Wilcox
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Histone deacetylase inhibitors and cell death
Jing Zhang et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2014)
Evaluation of the BH3-only Protein Puma as a Direct Bak Activator
Haiming Dai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Histone Deacetylase Inhibitor Sensitizes Apoptosis-Resistant Melanomas to Cytotoxic Human T Lymphocytes through Regulation of TRAIL/DR5 Pathway
Ali R. Jazirehi et al.
JOURNAL OF IMMUNOLOGY (2014)
Bak Core and Latch Domains Separate during Activation, and Freed Core Domains Form Symmetric Homodimers
Jason M. Brouwer et al.
MOLECULAR CELL (2014)
Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights
Prithviraj Bose et al.
PHARMACOLOGY & THERAPEUTICS (2014)
The Changing Landscape of Peripheral T-Cell Lymphoma in the Era of Novel Therapies
Lionel Karlin et al.
SEMINARS IN HEMATOLOGY (2014)
Genetics of Follicular Lymphoma Transformation
Laura Pasqualucci et al.
CELL REPORTS (2014)
Bax Crystal Structures Reveal How BH3 Domains Activate Bax and Nucleate Its Oligomerization to Induce Apoptosis
Peter E. Czabotar et al.
CELL (2013)
Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies
Mamta Gupta et al.
BLOOD (2012)
Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells
Delphine Merino et al.
BLOOD (2012)
Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis
Simone Fulda
EXPERIMENTAL CELL RESEARCH (2012)
Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation
Husheng Ding et al.
BLOOD (2011)
Deciphering the Molecular Events Necessary for Synergistic Tumor Cell Apoptosis Mediated by the Histone Deacetylase Inhibitor Vorinostat and the BH3 Mimetic ABT-737
Adrian P. Wiegmans et al.
CANCER RESEARCH (2011)
Vorinostat-Induced Apoptosis in Mantle Cell Lymphoma Is Mediated by Acetylation of Proapoptotic BH3-Only Gene Promoters
Silvia Xargay-Torrent et al.
CLINICAL CANCER RESEARCH (2011)
Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases
Andreas Strasser et al.
EMBO JOURNAL (2011)
High Cell Surface Death Receptor Expression Determines Type I Versus Type II Signaling
Xue Wei Meng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Noxa/Bcl-2 Protein Interactions Contribute to Bortezomib Resistance in Human Lymphoid Cells
Alyson J. Smith et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization
Haiming Dai et al.
JOURNAL OF CELL BIOLOGY (2011)
A Unified Model of Mammalian BCL-2 Protein Family Interactions at the Mitochondria
Fabien Llambi et al.
MOLECULAR CELL (2011)
Histone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions
Paul A. Marks
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2010)
HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells
R. Shimizu et al.
LEUKEMIA (2010)
Different forms of cell death induced by putative BCL2 inhibitors
M. Vogler et al.
CELL DEATH AND DIFFERENTIATION (2009)
Context-dependent Bcl-2/Bak Interactions Regulate Lymphoid Cell Apoptosis
Haiming Dai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
βTrCP- and Rsk1/2-Mediated Degradation of BimEL Inhibits Apoptosis
Elinor Dehan et al.
MOLECULAR CELL (2009)
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate
Yun Dai et al.
BLOOD (2008)
Anticancer therapy: boosting the bang of Bim
Andrea Wahner Hendrickson et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic
Mark S. Cragg et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin
Andrea Newbold et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Apoptosis: controlled demolition at the cellular level
Rebecca C. Taylor et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Bmf and Bmf in tissue homeostasis and malignant disease
J. D. Pinon et al.
ONCOGENE (2008)
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist
Ailsa J. Frew et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis
Mai Nguyen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents
Jing Deng et al.
CANCER CELL (2007)
Integrative genomic approaches identify IKBKE as a breast cancer oncogene
Jesse S. Boehm et al.
CELL (2007)
The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy
Jose A. Karam et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Regulation of Ras in lymphocytes: get a GRP
J. C. Stone
BIOCHEMICAL SOCIETY TRANSACTIONS (2006)
A stapled BID BH3 helix directly binds and activates BAX
Loren D. Walensky et al.
MOLECULAR CELL (2006)
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors
P Bali et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway
A Insinga et al.
NATURE MEDICINE (2005)
Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro
XW Meng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein
JL Aron et al.
BLOOD (2003)
Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim
R Ley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma
XBX Cao et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2001)
Reutilization of immunoblots after chemiluminescent detection
SH Kaufmann
ANALYTICAL BIOCHEMISTRY (2001)
分享论文
